These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8851646)

  • 1. The importance of considering non-monetary costs and benefits in selecting pharmacologic interventions in mental health.
    Pleil AM
    Psychopharmacol Bull; 1995; 31(4):727-34. PubMed ID: 8851646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry.
    Revicki DA; Luce BR
    Psychopharmacol Bull; 1995; 31(1):57-65. PubMed ID: 7675990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stepped care: doing more with less?
    Davison GC
    J Consult Clin Psychol; 2000 Aug; 68(4):580-5. PubMed ID: 10965633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The socioeconomic costs of mental illness in Spain.
    Oliva-Moreno J; López-Bastida J; Montejo-González AL; Osuna-Guerrero R; Duque-González B
    Eur J Health Econ; 2009 Oct; 10(4):361-9. PubMed ID: 19031056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of nine common mental disorders: implications for curative and preventive psychiatry.
    Smit F; Cuijpers P; Oostenbrink J; Batelaan N; de Graaf R; Beekman A
    J Ment Health Policy Econ; 2006 Dec; 9(4):193-200. PubMed ID: 17200596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the costs, benefits, cost-effectiveness, and cost-benefit of psychological assessment: we should, we can, and here's how.
    Yates BT; Taub J
    Psychol Assess; 2003 Dec; 15(4):478-95. PubMed ID: 14692844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving mental health treatments through comparative effectiveness research.
    Wang PS; Ulbricht CM; Schoenbaum M
    Health Aff (Millwood); 2009; 28(3):783-91. PubMed ID: 19414887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of the effects of financial risk on the formal treatment costs for a Medicaid population with psychiatric disabilities.
    Jones K; Chen HJ; Jordan N; Boothroyd RA; Ramoni-Perazzi J; Shern DL
    Med Care; 2006 Apr; 44(4):320-7. PubMed ID: 16565632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in mental health cost growth: an expanded role for management?
    Frank RG; Goldman HH; McGuire TG
    Health Aff (Millwood); 2009; 28(3):649-59. PubMed ID: 19414870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dialogue. Prescription for problems? Capitating mental health drugs--the great debate.
    Docherty JP; Browne RA; Farmer M
    Behav Healthc Tomorrow; 1998 Oct; 7(5):32-8. PubMed ID: 10185199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mental health in the Medicare Part D drug benefit: a new regulatory model?
    Donohue J
    Health Aff (Millwood); 2006; 25(3):707-19. PubMed ID: 16684735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Parameter of evidence-based medicine in health care economics].
    Wasem J; Siebert U
    Z Arztl Fortbild Qualitatssich; 1999 Aug; 93(6):427-36. PubMed ID: 10519192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Generics in psychiatry--do they have the same therapeutic equivalence as the original?].
    Kasper S; Lentner S
    Neuropsychiatr; 2008; 22(4):221-2. PubMed ID: 19080992
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost of treating mental illness from a managed care perspective.
    Docherty JP
    J Clin Psychiatry; 1999; 60 Suppl 3():49-52; discussion 53. PubMed ID: 10073378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empirically supported treatments for panic disorder: costs, benefits, and stepped care.
    Otto MW; Pollack MH; Maki KM
    J Consult Clin Psychol; 2000 Aug; 68(4):556-63. PubMed ID: 10965630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.